Treatment optimization for multiple myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in in vitro and ex vivo models

Haematologica. 2018 Dec;103(12):e602-e606. doi: 10.3324/haematol.2017.186924. Epub 2018 Jul 19.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Apoptosis / drug effects*
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / pharmacology
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / pathology*
  • Oligopeptides / administration & dosage
  • Oligopeptides / pharmacology*
  • Proteasome Inhibitors / administration & dosage
  • Proteasome Inhibitors / pharmacology
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives*
  • Thalidomide / pharmacology

Substances

  • Immunologic Factors
  • Oligopeptides
  • Proteasome Inhibitors
  • Thalidomide
  • carfilzomib
  • pomalidomide